Summary
Cough is a protective mechanism and an important symptom of many respiratory diseases. When coughing is only an annoying reflex and produces no mucus clearance, inducing fatigue or exhaustion for patients and worsening their pathological condition, antitussive drugs may be indicated.
In this study we evaluated the efficacy and safety of moguisteine, a new antitussive drug with a peripheral mechanism of action, in a population of 124 adult patients with persistent cough associated with various respiratory disorders. Obstructive chronic bronchitis, reported in about 50% of the study population, was the most frequent underlying diagnosis. We conducted a randomised single-blind short term treatment trial in 7 centres, comparing moguisteine (3 doses of 200mg, over 2 days) to dextromethorphan (3 doses of 30mg, over 2 days). The primary efficacy variable was the percentage reduction in the audio tape-recorded number of coughs during a 6-hour period in the morning after the last dose of the study drug versus a 6-hour recording at baseline.
Patients’ subjectively assessed visual analogue scale (VAS) scores of cough frequency and cough troublesomeness at night and during the morning were considered as secondary efficacy variables.
Safety was assessed by means of routine clinical laboratory tests and adverse event monitoring.
The postdrug percentage reduction in the number of coughs approached 30% on either drug. VAS scores of cough frequency and cough troublesomeness showed remarkable reductions in both groups, without any noteworthy difference between treatments. Possible or probable drug-related adverse events were reported in 3 of 61 patients on moguisteine (1 heartburn, 1 gastric pain, 1 diarrhoea) and in 4 of 63 patients on dextromethorphan (1 rhinitis and slight decrease of white blood cell count, 1 syncope, 1 gastric discomfort, 1 diarrhoea). Treatment discontinuation was necessary only for 1 patient, who had a syncope after the first dose of dextromethorphan.
Our results indicate that treatment with moguisteine rapidly induces substantial cough relief and that it is well tolerated and as effective as dextromethorphan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aversa C, Cazzola M, Clini V, Dal Negro R, Maiorano V, et al. Clinical trial on the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases. Drugs Under Experimental and Clinical Research, in press, 1994
Banner AS. Cough: physiology, evaluation and treatment. Lung 164: 79–92, 1986
Castoldi D, Oggioni A, Monzani V, Carlesi RM. Single dose kinetics of moguisteine in healthy male volunteers after oral and rectal administration. Pharmacological Research 22 (Suppl. 12): 102, 1990
Del Donno M, D’Ippolito R, Olivieri D. Mucociliary clearance in humans as physiologic lung defense mechanism. In Junoud et al. (Eds) Endothelial and mucus secreting cells, pp. 247–260, Masson, Milan, 1991
Eddy NB, Friebel H, Hahn KJ, Halbach H. Codeine and its alternatives for pain and cough relief. Part 3. Bulletin of the World Health Organization 40: 425–454, 1969
Gallico L, Borghi A, Dalla Rosa C, Ceserani R, Tognella S. Effect of dexamethasone and moguisteine on allergen-induced early bronchoconstriction and late phase airway leucocyte recruitment in sensitized guinea-pigs. British Journal of Pharmacology 106: 75P, 1992
Gallico L, Borghi A, Dalla Rosa C, Lumachi B, Tofanetti O, et al. BBR 2173, a new non narcotic antitussive agent. Pharmacological Research Communications 20 (Suppl. II): 171, 1988
Gallico L, Borghi A, Dalla Rosa C, Oggioni N, Lumachi B, et al. Moguisteine: a new drug effective in experimental cough and hyperreactivity. American Review of Respiratory Disease 141 (N4, part II): A654, 1990
Hughes DTD. Cough suppressants, expectorants, and mucolytic agents. British Medical Journal 1: 1202–1203, 1978
Irwin RS, Curley FJ. The treatment of cough: a comprehensive review. Chest 99: 1477–1484, 1991
Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and protussives: a practical review. Drugs 46: 80–91, 1993
Leith DE. Cough. In Brain et al. (Eds) Respiratory defense mechanism. Part III, pp. 545–592, Dekker, New York, 1977
Morikawa T, Gallico L, Widdicombe J. Actions of moguisteine on cough and pulmonary rapidly adapting receptor activity in the guinea pig. British Journal of Pharmacology, in press, 1994
Morrone L, Pizza A, Martinelli A, Chianese R, Merlo G, et al. Pilot study on efficacy and safety of a new antitussive drug, moguisteine: a double blind placebo controlled trial. Advances in Therapy 10: 67–73, 1993
Moscato G, Dellabianca A, Carlesi RM, Assereto R, Bertoletti R. Preliminary clinical experience with moguisteine in acetylcholine induced cough. European Respiratory Journal 3 (Suppl. 10): 93S, 1990
Pavia D, Agnew JE, Clarke SW. Cough and mucociliary clearance. Clinical Respiratory Physiology 23 (Suppl. 10): 41–45, 1987
Reynolds JE (Ed). Dextromethorphan hydrobromide. In Martindale. The Extra Pharmacopoeia, 29th ed., p. 908, Pharmaceutical Press, London, 1989
Sestini P, Refini RM, Pieroni MG, Ferretti B, Carlesi RM, et al. Protective effect of the new antitussive drug moguisteine on citric acid-induced cough. European Respiratory Journal 3 (Suppl. 10): 160S, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Donno, M., Aversa, C., Corsico, R. et al. Efficacy and Safety of Moguisteine in Comparison with Dextromethorphan in Patients with Persistent Cough. Drug Invest 7, 93–100 (1994). https://doi.org/10.1007/BF03257404
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03257404